Bottom line
In March 2024, the FDA approved Wegovy (semaglutide 2.4 mg weekly) for a new indication: reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. This made Wegovy the first anti-obesity medication in history to receive an FDA-approved cardiovascular benefit indication.
The approval was based on the SELECT trial — a landmark randomized, placebo-controlled trial of over 17,600 patients followed for a mean of 40 months. The headline finding: a 20% reduction in major adverse cardiovascular events (MACE) — the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke.
This changes three things:
1. The clinical case for GLP-1s in cardiovascular patients is now evidence-based, not speculative. 2. Insurance coverage for Wegovy should expand, because cardiovascular risk reduction is a recognized, reimbursable medical indication. 3. The prescribing conversation shifts — cardiologists and internists now have reason to prescribe Wegovy independently of endocrinologists and obesity specialists.
What SELECT actually measured
The trial enrolled adults aged 45+ with established atherosclerotic cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease) and BMI ≥27 — without type 2 diabetes (to isolate the obesity/CV effect from the diabetes effect).
Key design features:
- Semaglutide 2.4 mg/week vs placebo
- Mean follow-up: 39.8 months (~3.3 years)
- Primary endpoint: time to first MACE (CV death, non-fatal
MI, non-fatal stroke)
- Intent-to-treat analysis
Primary results:
- MACE occurred in 6.5% of the semaglutide group vs 8.0% of
the placebo group
- Hazard ratio: 0.80 (95% CI: 0.72-0.90)
- Number needed to treat: ~67 to prevent one MACE event
over ~3.3 years
Secondary endpoints:
- CV death alone: HR 0.85 (not statistically significant by
the pre-specified testing hierarchy, but directionally favorable)
- All-cause mortality: HR 0.81 (again directionally favorable,
not significant in hierarchy)
- Heart failure composite: HR 0.82 (significant)
- Kidney composite: HR 0.78 (significant)
What's notable: the cardiovascular benefit appeared to emerge early — within the first 12-18 months — and persisted throughout the trial. The benefit was present even in subgroups with relatively modest weight loss, suggesting the cardiovascular protection is not purely a function of pounds lost.
Why this matters beyond weight loss
Before SELECT, the clinical framing of GLP-1s for non-diabetic patients was purely about weight management. SELECT reframes semaglutide as a cardiovascular risk reduction drug that also happens to cause weight loss.
This distinction matters because:
- **Cardiovascular risk reduction is a stronger insurance
argument** than weight management. Many plans that exclude anti-obesity medications cover cardiovascular drugs. A prior authorization citing the SELECT data and the new FDA indication can open coverage pathways that were previously closed.
- Cardiologists can now prescribe independently. Before
SELECT, GLP-1 prescribing was largely the domain of endocrinologists and obesity medicine specialists. Cardiologists now have a direct reason to initiate therapy in their own patients.
- The standard of care is shifting. Major cardiology
guidelines are being updated to include semaglutide as a recommended therapy for secondary prevention in patients with atherosclerotic CVD and obesity.
What about tirzepatide?
Tirzepatide (Mounjaro/Zepbound) does not yet have cardiovascular outcome trial data. The SURPASS-CVOT trial is ongoing and results are expected in 2027 or later.
Many clinicians and patients extrapolate from SELECT to tirzepatide — "if semaglutide reduces CV events, tirzepatide probably does too." This is a reasonable hypothesis but it is not proven. Until SURPASS-CVOT reads out, the cardiovascular indication belongs to semaglutide alone.
For patients with both established cardiovascular disease and obesity, this is the strongest argument for semaglutide over tirzepatide in 2026: the evidence exists for one and not the other.
Other cardiovascular mechanisms
Beyond weight loss, GLP-1 receptor agonists appear to have direct cardiovascular effects:
- Anti-inflammatory effects. GLP-1 receptor activation
reduces C-reactive protein and other inflammatory markers. Chronic inflammation is a driver of atherosclerotic plaque progression.
- Improved endothelial function. GLP-1s improve blood
vessel dilation and reduce arterial stiffness in some studies.
- Reduced blood pressure. A modest but consistent 3-5
mmHg systolic reduction is observed across GLP-1 trials, attributed partly to weight loss and partly to direct vascular effects.
- Improved lipid profiles. Triglycerides drop
significantly on GLP-1s; LDL effects are modest.
- Reduced kidney disease progression. The FLOW trial
(semaglutide in diabetic kidney disease) showed a 24% reduction in kidney events, and SELECT showed kidney benefits in non-diabetic patients as well.
These pleiotropic effects — benefits beyond the primary mechanism of action — are why the cardiovascular benefit isn't simply proportional to weight lost. A patient who loses only 5% body weight on semaglutide may still get meaningful cardiovascular protection from the drug's direct vascular and anti-inflammatory effects.
Insurance implications
The cardiovascular indication opens a new prior-authorization pathway. Specifically:
Before SELECT:
- Wegovy PA required: BMI ≥30 (or ≥27 + comorbidity) +
prior weight-loss attempt. Many plans excluded it entirely as an "anti-obesity medication."
After SELECT / new indication:
- Wegovy can be submitted under the cardiovascular risk
reduction indication for patients with established ASCVD + BMI ≥27. This routes through a different formulary pathway and bypasses many anti-obesity medication exclusions.
- Some plans now cover Wegovy under the cardiology benefit
even when they don't cover it under the obesity benefit.
If your insurance has denied Wegovy as a weight-loss drug but you have established cardiovascular disease, a resubmission under the new cardiovascular indication — citing the SELECT trial and the updated FDA labeling — has a meaningfully higher chance of approval.
See our guide on appealing a GLP-1 insurance denial.
Heart failure
A separate but related finding: GLP-1s appear to improve outcomes in heart failure with preserved ejection fraction (HFpEF), which is the type of heart failure most closely associated with obesity.
The STEP-HFpEF trial showed that semaglutide improved Kansas City Cardiomyopathy Questionnaire scores (a measure of heart failure symptoms and quality of life), reduced body weight, and improved 6-minute walk distance in patients with HFpEF and obesity.
This is particularly relevant because HFpEF has historically had very few effective treatments. GLP-1 therapy may become a standard part of the HFpEF toolkit for obese patients, pending further data.
What to ask your prescriber
If you have heart disease and obesity:
- "Am I eligible for Wegovy under the cardiovascular
indication?"
- "Can we submit the prior authorization under the CV
risk reduction indication rather than the weight-loss indication?"
- "Should I be on semaglutide specifically given the SELECT
data, even if tirzepatide might produce more weight loss?"
- "How does this interact with my current cardiac medications
(statins, antihypertensives, anticoagulants)?"
- "What monitoring do you want — and how often — given my
cardiac history?"
What this means for you
If you have established cardiovascular disease and obesity or overweight, GLP-1 therapy is no longer an optional lifestyle intervention — it's an evidence-based cardiovascular risk reduction strategy with a number needed to treat comparable to statins. The SELECT data is strong enough to change the standard of care.
If you've been denied insurance coverage for Wegovy under the weight-loss indication, the cardiovascular indication may be a path forward. If you're already on a statin and an antihypertensive and are looking for additional cardiovascular protection, semaglutide now has a seat at that table.
Talk to your cardiologist or internist, not just your weight management provider. The conversation has expanded.